NDA 220256 · Azurity
Javadin
Clonidine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
276
54 Phase 3, 19 recruiting
FAERS reports
3
1 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 24, 2025.
JAVADIN is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with JAVADIN. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide...
Mechanism: Clonidine stimulates alpha-adrenoreceptors in the brain. Clonidine is not a central nervous system stimulant. Clonidine is a known antihypertensive agent. By stimulating alpha-adrenoreceptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance, renal vascular resistance, heart rate, and blood pressure.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- JAVADIN · CLONIDINE HYDROCHLORIDE 0.02MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- PeriOperative ISchemic Evaluation-2 TrialPivotal-lookingCompleted
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT01082874 · 10,010 participants · Start Jul 2010 · Primary completion Mar 2014
Drug: Active Clonidine; Placebo Clonidine and 2 more · For: Cardiovascular Disease
Sites: Cleveland, Ohio; Rosario, Argentina; Parkville, Australia · 23 sites in all
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Resistant Hypertension Optimal TreatmentPivotal-lookingStatus unknown
Instituto do CoracaoGovernment (non-federal)
NCT01643434 · 2,000 participants (planned) · Start Aug 2012 · Primary completion Dec 2013
Drug: Spironolactone; Clonidine · For: Hypertension
Sites: São Paulo, Brazil
- Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)Pivotal-lookingCompleted
University of EdinburghAcademic, hospital or other
NCT03653832 · 1,404 participants · Start Dec 11, 2018 · Primary completion Dec 14, 2023
Drug: Dexmedetomidine; Clonidine and 1 more · For: Critical Illness
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Blackpool, United Kingdom · 38 sites in all
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyPivotal-lookingCompleted
Heart Care FoundationAcademic, hospital or other
NCT00421863 · 1,111 participants · Start Feb 2005 · Primary completion Jan 2009
Drug: Triatec 10 mg; Triatec HCT 5 and 7 more · For: Hypertension
Sites: San Pietro Vernotico, Italy; Chiari, Italy; Trebisacce, Italy · 45 sites in all
- Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart SurgeryPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT05029050 · 900 participants (planned) · Start Jan 17, 2022 · Primary completion Jul 31, 2026
Drug: Dexmedetomidine; Clonidine and 1 more · For: Delirium; Cognitive Decline; Frailty
Sites: Bergen, Norway; Oslo, Norway; Tromsø, Norway · 5 sites in all
- Nephropathy In Type 2 Diabetes and Cardio-renal EventsPivotal-lookingCompleted
University of Campania Luigi VanvitelliAcademic, hospital or other
NCT00535925 · 850 participants · Start Oct 2005 · Primary completion Dec 2011
Drug: SoC therapy; irbesartan and 12 more · For: Diabetic Nephropathy
Sites: Naples, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1
- product prescribing issue1
- product primary packaging issue1
- product taste abnormal1
- product use in unapproved indication1
- product use issue1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Bohn E, Goren K, Switzer L, et al. · Dev Med Child Neurol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Clonidine for smoking cessation.
Gourlay SG, Stead LF, Benowitz NL · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White JM, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Postoperative analgesia by intravenous clonidine.
Bernard JM, Hommeril JL, Passuti N, et al. · Anesthesiology 1991 · Clinical Trial, Randomized Controlled Trial
- Clonidine in the treatment of hypertension.
Garrett BN, Kaplan NM · J Cardiovasc Pharmacol 1980 · Clinical Trial, Randomized Controlled Trial
- Clonidine blocks acute opiate-withdrawal symptoms.
Gold MS, Redmond DE, Kleber HD · Lancet 1978 · Clinical Trial, Randomized Controlled Trial
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.